Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): Evidence of antitumour activity

Expert Opinion on Biological Therapy

Volumn 5, Issue 3, 2005, Pages 293-311

  Everly, Jason J ^a   Lonial, Sagar ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dendritic cells; GM CSF; Immunomodulation

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 2; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN; VINCRISTINE;

AGED; AGITATION; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CHILL; CONFUSION; CONSTIPATION; CYTOKINE RELEASE; DENDRITIC CELL; DERMATITIS; DIZZINESS; DRUG EFFECT; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEMATOPOIETIC CELL; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOTENSION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATORY CELL; KIDNEY CARCINOMA; LUNG EDEMA; LYMPHOCYTOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALAISE; MALE; MELANOMA; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; OLIGURIA; PAIN; PROSTATE CANCER; REVIEW; SACCHAROMYCES; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; SURVIVAL; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; IMMUNOLOGIC FACTORS; NEOPLASMS;

EID: 17144409909     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.3.293     Document Type: Review

References (95)

1. GROOPMAN JE, MOLINA JM, SCADDEN DT et al.: Hematopoietic growth factors: biology and clinical applications. N. Engl. J. Med. (1989) 321:1449-1459. Review of cytokines and their function.
2. GABRILOVE JL: Introduction and overview of hematopoietic growth factors. Semin. Hematol. (1989) 26(Suppl. 2):1-4.
3. KLINGEMANN HG: Clinical applications of recombinant human colony-stimulating factors. Can. Med. Assoc. J. (1989) 10:137-142.
4. YEE GC: Focus on GM-CSF and G-CSF: promising biotherapeutics for use in hematology and oncology. Hosp. Formul. (1990) 25:943-948.
5. CAIRO MS: Review of G-CSF and GM-CSF effects on neonatal neutrophil kinetics. Am. J. Pediatr. Hematol. Oncol. (1989) 11:238-244.
6. MORSTYN G, LIESCHKE GJ, SHERIDAN W et al.: Pharmacology of the colony-stimulating factors. Trends Pharmacol. Sci. (1989) 10:154-159.
7. MORSTYN G, BURGESS AW: Hemopoietic growth factors: a review. Cancer Res. (1988) 48:5624-5637.
8. MlTSUYASU RT, GOLDE DW: Clinical role of granulocyte-macrophage colony-stimulating factor. Hematol. Oncol. Clin. North Am. (1989) 3:411-425.
9. RISSOAN MC, SOUMELIS V, KADOWAKI et al.: Reciprocal control of T helper cell and dendritic cell differentiation. Science (1999) 283:1183-1186.
10. SCHLIENGER K, CRAIGHEAD N, LEE KP et al.: Efficient priming of protein antigen-specific human CD4(+) T-cells by monocyte-denved dendritic cells. Blood (2000) 96:3490-3498.
11. OSUGI Y, VUCKOVIC S, HART DN: Myeloid blood CD11c(+) dendritic cells and monocyte-dcrived dendritic cells differ in their ability to stimulate T lymphocytes. Blood (2002) 100:2858-2866.
12. WALLER EK, ROSENTHAL H, SAGAR L: DC2 effect on survival following allogeneic bone marrow transplantation. Oncology (Hunting.) (2002) 16:19-26.
13. SHU S, PLAUTZ G, KRAUSS J et al.: Tumor immunology. JAMA (1997) 278:1972-1981.
14. ARMITAGE J: Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood (1998) 92:4491-4508.
15. SMALL E, REESE D, UM B et al.: Therapy of advanced prostate cancer with granulocyte-macrophage colony stimulating factor. Clin. Cancer Res. (1999) 5:1738-1744. Review of prostate cancer responses to GM-CSF.
16. RINI BI, WEINBERG V, BOK R, SMALL E: Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony stimulating factor in patients with serologic progression of prostate cancer. J. Clin. Oncol. (2003) 21:99-105.
17. LEBLANC G, SMALL E, BOK R et al.: Granulocyte-macrophage colony stimulating factor (GM-CSF) therapy for patients (Pts) with serologic progression after definitive local therapy. In: Proceedings of the Thirty-Seventh Annual Meeting of the American Society of Clinical Oncology. Perry MC (Ed.), San Francisco, USA (2001):182a (Abstract 724).
18. DREICER R, SEE WA, KLEINE EA: Phase II trial of GM-CSF in advanced prostate cancer. Invest. New Drugs (2001) 19:261-265.
19. GLASPY J: Therapeutic options in the management of renal cell carcinoma. Semin. Oncol. (2002) 29(Suppl. 7):41-46.
20. SCHER H, MOTZER R: Bladder and renal cell carcinomas. In: Harrison's Principals of Internal Medicine. Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (Eds), McGraw-Hill, New York, USA (2001).
21. RINI BI, STADLER WM, SPIELBERGER RT et al.: Granulocyte-macrophage-colony stimulating factor in metastatic renal cell carcinoma: a Phase 11 trial. Cancer (1998) 82(7):1352-1358.
22. WOS E, OLENCKI T, TUASON L et al.: Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma. Cancer (1996) 77(6):1149-1153.
23. CORREALE P, SABATINO S, MESSINESE R et al.: Renal cell carcinoma with granulocyte-macrophage-colony stimulating-factor (GM-CSF) and very low dose subcutaneous (s.c.) interleukin-2 (IL-2). In: Proceedings of the Thirty-Ninth Annual Meeting of the American Society of Clinical Oncology, Grunberg MD (Ed.), Chicago, USA (2003): 179 (Abstract 716).
24. LISSONI P, MENGO S, BUCOVEC R et al.: Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients. In Vivo (2003) 17(1):73-75.
25. SMITH JW II, KURT RA, BAHER AG et al.: Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized Phase I trial in patients with metastatic melanoma and renal cell carcinoma. J. Immunother. (2003) 26(2):130-138.
26. TATE J, OLENCKI T, FINKE J et al.: Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: clinical and laboratory effects. Ann. Oncol. (2001) 12(5):655-659.
27. HOTTON KM, KHORSAND M, HANK JA et al.: A Phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis. Cancer (2000) 88(8): 1892-1901.
28. DUTCHER J, CALIENDO G, NOVIK L et al.: Phase II study of moderate dose bolus or continuous infusion (CI) IL-2 plus GM-CSF in metastatic renal cell carcinoma (MRCC). In: Proceedings of the Thirty-Fifth Annual Meeting of the American Society of Clinical Oncology. Perry MC (Ed.), Atlanta, USA (1999):451a (Abstract 1740).
29. NAUGHTON MJ, HAUG J, DIPERSIO J et al.: A Phase 11 study of dendritic cell mobilization with GM-CSF in conjunction with IL-2 as immunotherapy for renal cell carcinoma (RCC), an initial report. In: Proceedings of the Thirty-Fifth Annual Meeting of the American Society of Clinical Oncology. Perry MC (Ed.), Atlanta, USA (1999):349a (Abstract 1344).
30. SCHILLER JH, HANK JA, KHORSAND M et al.: Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a Phase IB study. Clin. Cancer Res. (1996) 2(2):319-330.
31. VERRA N, JANSEN R, GROENEWEGEN G et al.: Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Br. J. Cancer (2003) 88(9):1346-1351.
32. SCHMIDINGER M, STEGER G, WENZEL C et al.: Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a Phase II trial. J. Immunother. (2001) 24(3):257-262.
33. WESTERMANN J, REICH G, KOPP J et al.: Granulocyte/macrophage-colony- stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study. Cancer Immunol. Immunother. (2001) 49(11):613-620.
34. DE GAST GC, KLUMPEN HJ, VYTH-DREESE FA et al.: Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res. (2000) 6(4):1267-1272.
35. RYAN CW, VOGELZANG NJ, DUMAS MC et al.: Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two Phase II clinical trials. Cancer (2000) 88(6):1317-1324. Phase II trials of GM-CSF in RCC.
36. RAO RD, ANDERSON PM, ARNDT CA et al.: Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am. J. Clin. Oncol. (2003) 26(5):493-498.
37. SCHWAAB T, TRETTER CP, GIBSON JJ et al.: Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma. J. Urol. (2004) 171(3):1036-1042.
38. JAMES N, ATHERTON P, KOLESTSKY A et al.: Phase 11 trial of the bispecific antibody MDX-H210 (anti-HER2/neu × anti-CD64) combined with GM-CSF in patients with advanced prostate and renal call carcinomas that express HER2/neu. In: Proceedings of the Thirty-Fourth Annual Meeting of the American Society of Clinical Oncology. Perry MC (Ed.), Los Angeles, USA (1998):436a (Abstract 1681).
39. PLAUTZ G, BUKOWSKI R, NOVICK A et al.: T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urol. (1999) 54:617-624.
40. LOTZE MT, DALLAL RM, KIRKWOOD JM et al.: Cutaneous melanoma. In: Cancer. Principals and Practice of Oncology. De Vita V, Hellman S, Rosenberg SA (Eds), Lipincott Williams and Wilkins, Philadelphia, USA (2001).
41. SPITLER LE, GROSSBARD ML, ERNSTOFF MS et al.: Adjuvant therapy of stage 111 and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. (2000) 18(8):1614-1621.
42. SPITLER LE, GROSSBARD ML, ERNSTOFF MS et al.: Adjuvant therapy of stage 111 and IV melanoma using granulocyte-macrophagecolony-stimulating factor. In: Proceedings of the Thirty-Fourth Annual Meeting of the American Society of Clinical Oncology. Perry MC (Ed.), San Francisco, USA (2001):358a (Abstract 1429).
43. O'DAY SJ, BOASBERG PD, PIRO L et al.: Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin. Cancer Res. (2002) 8(9):2775-2781.
44. RAVAUD A, DELAUNAY M, CHEVREAU C et al.: Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized Phase II trial. Br. J. Cancer (2001) 85(10):1467-1471.
45. VAUGHAN MM, MOORE J, RICHES PG et al.: GM-CSF with biochemotherapy (cisplatin, DT1C, tamoxifen, IL-2 and interferon-alpha): a Phase I trial in melanoma. Ann. Oncol. (2000) 11(9):1183-1189.
46. GROENEWEGEN G, DE CAST GC: GM-CSF can cause T cell activation; results of sequential chemo-immunotherapy. Eur. J. Cancer (1999) 35(Suppl. 3):S23-S24.
47. GAJEWSKI T, FLICKINGER S: A Phase II study of outpatient chemoimmunotherapy using cisplatin and DTIC followed by GM-CSF, IL-2 and INF-alpha-2b in patients (Pts) with metastatic melanoma. In: Proceedings of the Thirty-Sixth Annual Meeting of the American Society of Clinical Oncology. Perry MC (Ed.), New Orleans, USA (2000):576a (Abstract 2271).
48. GIBBS O, O'DAY S, RICHARDS J et al.: A multicenter Phase II study of modified biochemotherapy (BCT) for stage IV melanoma incorporating temozolomide, decrescendo interleukin-2 (IL-2) and GM-CSF. In: Proceedings of the Thirty-Sixth Annual Meeting of the American Society of Clinical Oncology. Perry MC (Ed.), New Orleans, USA (2000):572a (Abstract 2255).
49. LUTZKY J, BLAUSTEIN A, WEINGRAD et al.: Phase I/II study of GM-CSF and thalidomide in patients with high-risk malignant melanoma. In: Proceedings of the Thirty-Ninth Annual Meeting of the American Society of Clinical Oncology. Long MC (Ed.), Chicago, USA (2003):725 (Abstract 2916).
50. WEBER R, ROSE M, GOOD J et al.: A Phase II trial of chemobiotherapy with temozolomide, GM-CSF, interferon-alpha-2b, and interleukin-2 in patients with metastatic melanoma. Thirty-Ninth Annual Meeting of the American Society of Clinical Oncology. Chicago, USA (2003). Poster Presentation.
51. DE GAST GC, BATCHELOR D, KERSTEN MJ et al.: Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. Br. J. Cancer (2003) 88(2):175-180.
52. GROENEWEGEN G, BLOEM A, DE GAST GC: Phase 1/11 study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha. Cancer Immunnol. Immunother. (2002) 51(11-12):630-636.
53. JANIK JE, MILLER LL, KORN EL et al.: A prospective randomized Phase 11 trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. Blood (2001) 97(7):I942-I946.
54. SCHACHTER J, RAKOWSKY E, SULKES A: A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF-an innovative protocol for the treatment of metastatic melanoma. Cancer Biother Radiopharm. (1998) 13:155-164.
55. BANCHEREAU J, PALUCKA AK, DHODAPKAR M et al.: Immune and clinical responses in patients with metastatic melanoma to CD34 (+) progenitor-derived dendritic cell vaccine. Cancer Res. (2001) 61 (17):6451-6458.
56. PINEDO HM, BUTER J, LUYKX-DE BAKKER SA et al.: Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: effect on tumour-draining lymph node dendritic cells. Eur. J. Cancer (2003) 39(8):1061-1067. Paper demonstrating DC effects using GM-CSF in combination with chemotherapy for breast cancer.
57. SIMONS JW, MIKHAK B, CHANG JF et al.: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. (1999) 59(20):5160-5168. First paper to use GM-CSF-transduced tumour vaccines in prostate cancer.
58. IDEC Pharmaceuticals Corporation: Rituxan® package insert. San Diego, CA, USA.
59. VENUGOPAL P, SIVARAMAN S, HUANG XK et al.: Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk. Res. (2000) 24(5):411-415.
60. DESHPANDE CG, SIVARAMAN S, CONNOR T et al.: Effect of GM-CSF and/or IL-2 on Rituxan® induced cellular apoptosis on DHL-4 cells. Blood (1999) 94(Suppl. I):254b (Abstract 4304). Clinical paper demonstrating the benefits of adjuvant GM-CSF following therapy for high-risk melanoma.
61. SIVARAMAN S, DESHPANDE CG, KUNKEL L et al.: Rituxan® induced apoptosis in DHL-4 cells: effect of IL-4 and GM-CSF. Blood (1999) 94(SuPPl. I):254b (Abstract 4344).
62. PEARSON MD, BUJ V, SHINN C et al.: GM-CSF treatment does not up-regulate expression of CD20 in vivo in patients with chronic lymphocytic leukemia. Blood (1999) 94(Suppl. I):245b (Abstract 717).
63. VOSO MT, PANTEL G, RUTELLA S et al.: Effector cell-mediated mechanisms play the dominant role in the cytotoxicity of rituximab on human peripheral blood B cells from normal donors and patients with chronic lymphocytic leukemia. Blood (2000) 96(11):338a (Abstract 1462).
64. LIU N, GRIMM E, POINDEXTER N et al.: Antibody dependant cellular cytotoxicity and natural killer cell activity in patients with recurrent indolent lymphoma receiving rituximab in combination with GM-CSF. Proceedings of the Forty-Fifth Annual Meeting of the American Society of Hematology. San Diego, USA (2003). Poster Presentation. Clinical trial demonstrating improved rituxan responses with GM-CSF.
65. JANAKIRAMAN N, GAUTAM S, XU Y et al.: Rituxan plus GM-CSF for the treatment of low grade follicular (B cell) non-Hodgkin's lymphoma (NHL). Blood (2001) 98(11):243b (Abstract 4698).
66. ROSSI JF, YANG LZ, QUITTET P et al.: RITUXIMAB (Rab) and GM-CSF, an effective therapy for relapsed/refractory patients (pts) with low-grade B-cell lymphoma (L): correlation between response and dendritic cell (DC) subpopulation mobilized. Blood (2001) 98(11):607a (Abstract 2542).
67. VENUGOPAL P, GREGORY S, SHOWEL JL et al.: ESHAP combined with rituximab and GMCSF is highly active in relapsed/refractory aggressive lymphoma. Blood (2003) 102:Abstract 4950.
68. VENUGOPAL P, WOOLDRIDGE J, YUMUS F et al.: Chemoimmunotherapy with combination of rituximab, GMCSF and CHOP in patients previously untreated aggressive non-Hodgkin's lymphoma. Blood (2003) 102:Abstract 4930.
69. SHAH PK, IFTHIKHARUDDIN J, MINTZ M et al.: 2-chlorodeoxyadenosine (2-CDA) with weekly rituximab and granulocyte-macrophage colony stimulating factor (GM-CSF): a highly effective regimen for advanced B-cell lymphoproliferative disorders (BLPD). Blood (2001) 98(11):249b (Abstract 4726).
70. OLIVIERI A, CAPELLI D, LUCESOLE M et al.: A new strategy with CHOP-rituximab (RTX) plus GM-CSF in the salvage treatment of 33 patients with aggressive NHL. Blood (2001) 98(11):245b (Abstract 4709).
71. LIU NS, GRIMM E, POINDEXTER N et al.: Antibody dependent cellular cytotoxicity and natural killer cell activity in patients with recurrent indolent lymphoma receiving rituximab in combination with GM-CSE Proc. Am. Soc. Hematol. (2003):Abstract 1495.
72. WALLER EK, ROSENTHAL H, JONES TW et al.: Larger numbers of CD4 (bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood (2001) 97(10):2948-2956. First clinical paper to demonstrate that DC content of graft can impact survival following allogeneic BMT.
73. HOROWITZ MM, GALE RP, SONDEL PM et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 75(3):555-562.
74. ARPINATI M, GREEN CL, HEIMFELD S et al.: Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood (2000) 95:2484-2490.
75. LONIAL S, ROSENTHAL H, FEINSTEIN B et al.: A randomized study of G-CSF versus the combination of G-CSF/GM-CSF on mobilization of dendritic cells in peripheral blood stem cell grafts. Proc. Am. Soc. Hematol. (2000) 96:518a (Abstract 2229).
76. JOSHI SS, LYNCH JC, PAVLETlC SZ et al.: Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics. Blood (2001) 98(6):1963-1970.
77. VOLPI I, PERRUCCIO K, TOSTI A et al.: Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood (2001) 97(8):2514-2521.
78. LONIAL S, TORRE C, HICKS M et al.: Modulation of allogeneic PBPC graft contents using G-CSF or G-CSF + GM-CSF: preliminary results from a randomized trial. Proc. Am. Soc. Hematol. (2003):Abstract 3551.
79. LONIAL S, HICKS M, ROSENTHAL H et al.: A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol. Blood Marrow Transplant. (2004) 10(12):848-857. First randomised trial to demonstrate that cytokines can impact DC subsets in a PBSC graft.
80. SIMMONS JW, MIKHAK B, CHANG JF et al.: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate cancer tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. (1999) 59:5160-5168.
81. SOIFFER R, LYNCH T, MIHM M et al.: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA (1998) 95:13141-13146.
82. KUSUMOTO M, UMEDA S, IKUBO A et al.: Phase I clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol. Immunother. (2001) 50(7):373-381.
83. JAFFEE EM, HRUBAN RH, BIEDRZYCKI B et al.: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a Phase I trial of safety and immune activation. Clin. Oncol. (2001) 19(1):145-156.
84. NELSON WG, SIMONS JW, MIKHAK B et al.: Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vino gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother. Pharmacol. (2000) 46(Suppl.):S67-S72.
85. SIMONS JW, MIKHAK B: Ex vino gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology. Semin. Oncol. (1998) 25(6):661-676.
86. WEERATNA RD, MCCLUSKIE, XU Y et al.: CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine (2000) 18:1755-1762.
87. SCHAED SG, KLIMEK VM, PANACEAS KS et al.: T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201 + melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin. Cancer Res. (2002) 8(5):967-972.
88. JAGER E, RINGHOFFER M, DIENES HP et al.: Granulocyte-macrophage-colony- stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer (1996) 67(1):54-62.
89. SCHEIBENBOGEN C, SCHMITTEL A, KEILHOLZ U et al.: Phase II trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J. Immunother. (2000) 23(2):275-281.
90. SCHEIBENBOGEN C, SCHADENDORF D, BECHRAKIS NE et al.: Effects of granuloqte-macrophage colony-stimulating factor and foreign helper protein as immunological adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int. J. Cancer (2003) 104(2):188-194.
91. WEBER J, SONDAK VK, SCOTLAND R et al.: Granulocyte-macrophage-colony- stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer (2003) 97(1):186-200.
92. DISIS ML, GOOLEY TA, RINN K et al.: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. (2002) 20(11):2624-2632.
93. KWAK LW, YOUNG HA, PENNINGTON RW et al.: Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/ macrophagecolony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA (1996) 93(20):10972-10977.
94. TIMMERMAN JM, LEVY R: Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J. Immunol. (2000) 164(9):4797-4803.
95. PASQUINI S, PERALTA S, MISSIAGLIA E et al.: Prime-boost vaccines encoding an intracellular idiotype/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemia. Gene Ther. (2002) 9(8):503-510.